Update on Systemic Therapy for Advanced Soft Tissue Sarcoma
نویسندگان
چکیده
منابع مشابه
Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
Sarcomas are a group of rare solid tumours arising from mesenchymal or connective tissue. This review focuses on soft tissue sarcoma and covers general topics such as the epidemiology, age distribution, site of disease, histogenesis, histological subtypes, prognosis and outcome of treatment. In more detail, the article reviews current systemic treatment standards and selected adverse events of ...
متن کاملSystemic Therapy for Advanced Soft Tissue Sarcomas
Soft tissue sarcomas (STS) are a rare, heterogeneous group of solid tumors in need of improved therapeutic options. First-line chemotherapy is considered the current standard of care for patients with advanced, symptomatic STS, but the median survival is only 8 to 12 months. Efforts to increase response rates by using combination or dose-dense regimens have largely failed to improve patient out...
متن کاملSystemic therapy of soft tissue sarcoma: an improvement in outcome.
Systemic therapy for the majority of patients with soft tissue sarcoma who require treatment of advanced unresectable or metastatic disease remains very unsatisfactory. Ifosfamide and doxorubicin remain the only agents in routine use. Treatment is usually given with palliative intent, and single-agent doxorubicin is generally regarded as the drug of choice. Inevitably, there have been efforts t...
متن کاملManagement of Advanced Adult Soft Tissue Sarcoma
The rare incidence and heterogeneous nature of soft tissue sarcomas (STS) are formidable barriers to the conduct of large randomised controlled trials (RCTs). A search of computer databases, using a Cochrane optimal search strategy 1966–1996, yielded less than 100 RCTs investigating the management of bone and soft tissue sarcomas (Bramwell 1997, Proceedings 5th Annual Cochrane Colloquium – unpu...
متن کاملSystemic Treatment for Advanced Soft Tissue Sarcoma beyond Doxorubicin and Ifosfamide
Systemic therapy is the backbone in the management of advanced soft-tissue sarcoma.At present, anthracycline-based regimes represents the standard first-line treatment, but there are other active drugs widely used, providing additional therapeutic options and increasing overall survival among patients with advanced disease. Histologic subtype, patient characteristics, and expected toxicity prof...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2020
ISSN: 1718-7729,1198-0052
DOI: 10.3747/co.26.5475